Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (3955)	3/24/1998 2:20:00 PM
From: Peter Singleton	Read Replies (1) of 6136

Margie, wow, what a great post. Do you have the detailed IMS data for February? If so, could you post (actual numbers for all the PIs + IMS adjustment factor). A couple of points. 1 - I thought the Fortovase+Invirase combined scrips were increasing market share, based on (the very early) data in December and January. I wasn't aware they flattened out in February. Who picked up the slack if Viracept and Ritonavir were flat, and Crixivan dropped? You're right of course that the relevant market share # for Roche is the combined number. 2 - The Fortovase clinical data I was referring to were published in Chicago ... showing excellent efficacy and tolerability, seemingly on a par with Viracept. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next